BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38534952)

  • 21. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States.
    Paluri R; Laursen A; Gaeta J; Wang S; Surinach A; Cockrum P
    Oncologist; 2022 Jun; 27(6):e518-e523. PubMed ID: 35285490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical relevance of the M1b and M1c descriptors from the proposed TNM 8 classification of lung cancer.
    Tufman A; Kahnert K; Kauffmann-Guerrero D; Manapov F; Milger K; Müller-Lisse U; Winter H; Huber RM; Schneider C
    Strahlenther Onkol; 2017 May; 193(5):392-401. PubMed ID: 28246699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.
    Risteski M; Crvenkova S; Atanasov Z; Isjanovska R
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(3):49-61. PubMed ID: 24566015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transportability of Overall Survival Estimates From US to Canadian Patients With Advanced Non-Small Cell Lung Cancer With Implications for Regulatory and Health Technology Assessment.
    Ramagopalan SV; Popat S; Gupta A; Boyne DJ; Lockhart A; Hsu G; O'Sullivan DE; Inskip J; Ray J; Cheung WY; Griesinger F; Subbiah V
    JAMA Netw Open; 2022 Nov; 5(11):e2239874. PubMed ID: 36326765
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the COVID-19 pandemic on breast, colorectal, lung, and prostate cancer stage at diagnosis according to race.
    Berrian J; Liu Y; Ezenwajiaku N; Moreno-Aspitia A; Holton SJ; Toriola AT; Colditz GA; Housten AJ; Hall L; Fiala MA; Ademuyiwa FO
    Cancer Med; 2023 Mar; 12(6):7381-7388. PubMed ID: 36404491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 27. Prioritization of head and neck cancer patient care during the COVID-19 pandemic: a retrospective cohort study.
    Psycharis SS; Salameh S; Turkdogan S; Razzaq S; Zhao K; Mascarella MA; Richardson K; Mlynarek AM; Hier MP; Sadeghi N
    J Otolaryngol Head Neck Surg; 2023 Feb; 52(1):15. PubMed ID: 36782236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended Delay to Treatment for Stage III-IV Non-Small-Cell Lung Cancer and Survival: Balancing Risks During the COVID-19 Pandemic.
    Mayne NR; Bajaj SS; Powell J; Elser HC; Civiello BS; Fintelmann FJ; Li X; Yang CJ
    Clin Lung Cancer; 2022 Sep; 23(6):e362-e376. PubMed ID: 35660355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
    Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
    Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.
    Maringe C; Spicer J; Morris M; Purushotham A; Nolte E; Sullivan R; Rachet B; Aggarwal A
    Lancet Oncol; 2020 Aug; 21(8):1023-1034. PubMed ID: 32702310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pan-Canadian survey on the impact of the COVID-19 pandemic on cervical cancer screening and management: cross-sectional survey of healthcare professionals.
    El-Zein M; Ali R; Farah E; Botting-Provost S; Franco EL;
    Elife; 2023 Jun; 12():. PubMed ID: 37377399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by
    Vadagam P; Waters D; Lee I; Chen J; Tian D; Near AM; Lyle D; Vanderpoel J
    J Med Econ; 2024; 27(1):219-229. PubMed ID: 38269536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent versus sequential chemoradiotherapy for unresectable locally advanced stage III non-small cell lung cancer: Retrospective analysis in a single United Kingdom cancer centre.
    Spencer A; Williams J; Samuel R; Boon IS; Clarke K; Jain P
    Cancer Treat Res Commun; 2021; 29():100460. PubMed ID: 34598059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
    Debieuvre D; Juergens RA; Asselain B; Audigier-Valette C; Auliac JB; Barlesi F; Benoit N; Bombaron P; Butts CA; Dixmier A; Gröschel A; Gutz S; Labbé C; Moro-Sibilot D; Pérol M; Raspaud C; Schumann C; Juarez-Garcia A; Lakhdari K; Pettersson F; Penrod JR; Reynaud D; Waldenberger D; Allan V; Sebastian M
    Lung Cancer; 2021 Jul; 157():40-47. PubMed ID: 33980420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis of different extrathoracic metastasis patterns in patients with M1c lung adenocarcinoma receiving immunotherapy.
    Hu F; Peng J; Mao X; Niu Y; Ma M; Zhao Y; Gu A; Jiang L
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3171-3184. PubMed ID: 35882652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
    Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
    Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.
    Fornacon-Wood I; Banfill K; Ahmad S; Britten A; Carson C; Dorey N; Hatton M; Hiley C; Thippu Jayaprakash K; Jegannathen A; Kidd AC; Koh P; Panakis N; Peedell C; Peters A; Pope A; Powell C; Stilwell C; Thomas B; Toy E; Wicks K; Wood V; Yahya S; Price G; Faivre-Finn C
    Clin Oncol (R Coll Radiol); 2023 Oct; 35(10):e593-e600. PubMed ID: 37507280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.
    Kiss Z; Gálffy G; Müller V; Moldvay J; Sárosi V; Pápai-Székely Z; Csada E; Kerpel-Fronius A; Király Z; Szász Z; Hódi G; Polányi Z; Kovács K; Karamousouli E; Knollmajer K; Szabó TG; Berta A; Vokó Z; Rokszin G; Abonyi-Tóth Z; Barcza Z; Tamási L; Bogos K
    Front Oncol; 2023; 13():1207295. PubMed ID: 37860193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study.
    Lee-Ying R; O'Sullivan DE; Gagnon R; Bosma N; Stewart RN; Railton C; Tilley D; Alimohamed N; Basappa N; Cheng T; Kolinsky M; Karim S; Ruether D; North S; Yip S; Danielson B; Heng D; Brenner D
    CMAJ Open; 2022; 10(3):E633-E642. PubMed ID: 35790231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-Term Outcomes of COVID-19 Pandemic on Non-Small Cell Lung Cancer Screening and Management.
    Orelaru F; Edwards M; Raleigh R; Abunayla A; Bush R; Porter S; Schumaker K; Albright J; Adams KN
    Surg J (N Y); 2023 Oct; 9(4):e156-e161. PubMed ID: 38197091
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.